Dec 24 2012
According the results of a randomized control trial involving almost 2500 patients reported in the New England Journal of Medicine, twelve months of treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) at either of two dosages, given after six to 12 months of anticoagulation to treat venous thromboembolism (VTE), significantly lowered the risk of recurrent VTE compared with placebo. See the NEJM article below.
Comments (0)
Anticoagulant Therapy
No comments here.